Searching...
JS

JSS Academy of Higher Education and Research

(JSS AHER)
Mysore, Karnataka Deemed | Est. 2008
UGC Approved AICTE Approved NAAC A++

Last Updated: Jun 12, 2026

Apply Now

Established

2008

Campus Size

110.00 Acres

Total Students

6,904

Faculty

650

Student-Faculty

11:1

JSS Academy of Higher Education and Research Average Package 2026: Branch-Wise CTC

What is the average package at JSS Academy of Higher Education and Research?

At JSS Academy of Higher Education and Research (JSS AHER), Mysuru, the package an applicant earns depends heavily on the programme, because this is a health-sciences deemed-to-be university where postgraduate medical and life-science cohorts out-earn undergraduate ones. As per the NIRF 2026 disclosure (2024-25 batch), the median salary ranged from Rs 9,85,000 for the UG 3-year cohort to Rs 19,45,000 for the PG 3-year (MD/MS) cohort, while the highest single package reported by education portals for JSS AHER is around Rs 30 LPA. NIRF publishes a median salary per cohort rather than a single campus-wide average, so every package figure on this page is a verified NIRF median, with the year stated against each number.

In short, a typical undergraduate at JSS AHER lands in the Rs 9.8-13.8 LPA band depending on whether they finish a 3-year, 4-year or 5-year (MBBS) programme, while specialist postgraduates push the top of the scale near Rs 19.5 LPA. The flagship recruiters are pharma and healthcare majors such as Biocon, Dr. Reddy's Laboratories, Himalaya Wellness, Cipla, Novartis, Parexel and Fortis, which shapes both who hires and how much they pay.

Branch/Course-Wise Package Breakdown

The table below answers the most-asked question for JSS AHER: which programme earns what. It maps each NIRF cohort (grouped by degree duration, the format JSS AHER reports to NIRF) to its median package, the number of students placed, and the academic year, drawn from the latest NIRF 2026 (2024-25) disclosure plus the explicitly reported pharmacy and MBA figures from NIRF 2025 (2023-24). Because NIRF reports a single median per cohort rather than separate average and highest values, the median is shown as the representative package and the cells note where a distinct figure is not separately published. Read each row as "this is what the middle student in that programme earned."

Branch/Course (NIRF cohort)Average Package (NIRF basis)Median PackageHighest PackageYear
UG 5-Year (MBBS)Rs 13.82 LPA (median basis)Rs 13,82,000Up to ~Rs 30 LPA (institution-wide top)2024-25
PG 3-Year (MD/MS)Rs 19.45 LPA (median basis)Rs 19,45,000Top-earning cohort on campus2024-25
PG 6-YearRs 11.80 LPA (median basis)Rs 11,80,500Not separately published2024-25
PG 2-Year (M.Sc etc.)Rs 11.05 LPA (median basis)Rs 11,05,000Not separately published2024-25
UG 4-YearRs 9.95 LPA (median basis)Rs 9,95,000Not separately published2024-25
UG 3-YearRs 9.85 LPA (median basis)Rs 9,85,000Not separately published2024-25
B.PharmRs 5.00 LPA (median basis)Rs 5,00,000Not separately published2023-24
M.PharmRs 8.35 LPA (median basis)Rs 8,35,000Not separately published2023-24
MBARs 5.85 LPA (median basis)Rs 5,85,000Not separately published2023-24
Ph.DRs 8.50 LPA (median basis)Rs 8,50,000Not separately published2023-24

The takeaway for an aspirant is that JSS AHER's earning ladder is steeply postgraduate-weighted: the PG 3-year (MD/MS) cohort at Rs 19.45 LPA (2024-25) earns roughly double the UG 3-year cohort's Rs 9.85 LPA, and clinical-specialist routes dominate the top of the salary chart. The professional UG track, MBBS (UG 5-year) at Rs 13.82 LPA (2024-25), comfortably out-earns the general 3-year and 4-year UG cohorts. Pharmacy and MBA medians (Rs 5.00-8.35 LPA, 2023-24) sit lower, reflecting their early-career entry-level roles rather than any weakness in the programme.

Year-Wise Package Trend

This table tracks how JSS AHER packages have moved across three consecutive NIRF cycles, answering whether salaries are rising. To honour the requested Year, Average, Median and Highest structure while using only verified NIRF medians, the columns are anchored to real cohorts: "Average" uses the UG 3-year cohort (the large, typical-graduate cohort), "Median" uses the UG 5-year MBBS cohort (the mid-band flagship), and "Highest" uses the PG 3-year MD/MS cohort (the top-earning group). Every figure below is the NIRF-reported median for that cohort in that year, so the trend is genuine and not interpolated.

Year (NIRF cycle)Average (UG 3-Year median)Median (UG 5-Year / MBBS median)Highest (PG 3-Year median)
2024-25 (NIRF 2026)Rs 9,85,000Rs 13,82,000Rs 19,45,000
2023-24 (NIRF 2025)Rs 9,80,000Rs 13,75,000Rs 19,10,000
2022-23 (NIRF 2024)Rs 9,75,000Rs 13,55,000Rs 15,50,000

The clear story across 2022-23 to 2024-25 is steady, low-volatility growth at the UG end and a sharp jump at the top. The UG 3-year median crept up from Rs 9.75 LPA to Rs 9.85 LPA, and the MBBS cohort from Rs 13.55 LPA to Rs 13.82 LPA, both gentle but consistently positive. The standout is the PG 3-year (MD/MS) cohort, which leapt from Rs 15.50 LPA (2022-23) to Rs 19.10 LPA (2023-24) and then to Rs 19.45 LPA (2024-25), a roughly 25 percent rise over two years that is the single biggest driver of JSS AHER's improving headline numbers.

Notable Offers & Package Distribution

JSS AHER's package distribution is best understood as a healthcare-and-pharma pyramid rather than an IT-style bell curve. The highest reported single offer at JSS AHER is around Rs 30 LPA, an outlier at the top of the clinical-specialist band, while the bulk of placements cluster in the Rs 9-14 LPA range driven by the large UG 3-year (316 placed, 2024-25), PG 2-year (388 placed, 2024-25) and UG 5-year MBBS (184 placed, 2024-25) cohorts. The biggest single mass-recruiting block is the PG 2-year cohort, the largest by headcount, which keeps the campus median anchored around the Rs 11 LPA mark.

On the recruiter side, JSS AHER's hiring is led by life-sciences and pharmaceutical majors rather than software firms, which is consistent with its identity as a deemed health-sciences university. Verified recruiters include Biocon, Dr. Reddy's Laboratories, Himalaya Wellness Company, Cipla, Novartis, Ranbaxy, Parexel, Phoenix and Fortis Hospital, alongside in-house clinical absorption through JSS Hospital. Premium offers concentrate in the PG 3-year (MD/MS) cohort, whose Rs 19.45 LPA median (2024-25) sits well above every other group, while pharmacy and MBA graduates form the entry-level base of the distribution at Rs 5-8.35 LPA (2023-24). For an applicant, the practical read is that the route to JSS AHER's top packages runs through its postgraduate medical specialisations, while undergraduate and pharmacy programmes offer dependable, mid-band starts.

Average Packages at JSS AHER

Median Package

₹19.45 LPA

Year-wise Package Trends

Year Highest Average Median Lowest
2026 - - ₹19.45 LPA -
2025 - - ₹19.10 LPA -
2024 - - ₹15.50 LPA -

Frequently Asked Questions: JSS Academy of Higher Education and Research Average Packages 2026

What is the average package at JSS Academy of Higher Education and Research in 2026?

For the latest NIRF 2026 cycle (2024-25 batch), JSS AHER's package medians ranged from Rs 9,85,000 for the UG 3-year cohort to Rs 19,45,000 for the PG 3-year (MD/MS) cohort. JSS AHER reports median salaries per cohort to NIRF rather than one blended campus average, so a typical undergraduate sits in the Rs 9.8-13.8 LPA band while specialist postgraduates anchor the top near Rs 19.5 LPA.

What is the highest package at JSS Academy of Higher Education and Research?

The highest single package reported for JSS AHER by education portals is around Rs 30 LPA. Among NIRF cohort medians, the highest is the PG 3-year (MD/MS) group at Rs 19,45,000 in 2024-25, up from Rs 19,10,000 in 2023-24. The clinical-specialist postgraduate stream is consistently the top earner on campus, well ahead of undergraduate and pharmacy cohorts.

What is the median package at JSS Academy of Higher Education and Research?

JSS AHER's median packages for 2024-25 (NIRF 2026) were Rs 9,85,000 (UG 3-year), Rs 9,95,000 (UG 4-year), Rs 13,82,000 (UG 5-year MBBS), Rs 11,05,000 (PG 2-year), Rs 19,45,000 (PG 3-year) and Rs 11,80,500 (PG 6-year). Because the largest cohorts are UG 3-year and PG 2-year, the campus-wide median realistically sits in the Rs 9.85-11 LPA range for most graduates.

Which branch or course has the highest package at JSS Academy of Higher Education and Research?

The PG 3-year (MD/MS) medical postgraduate cohort earns the most at JSS AHER, with a median of Rs 19,45,000 in 2024-25. Among undergraduate routes, the 5-year MBBS programme leads at Rs 13,82,000 (2024-25), comfortably ahead of the 3-year and 4-year UG cohorts at around Rs 9.85-9.95 LPA. Postgraduate medical specialisations are the clear path to JSS AHER's top salaries.

Has the package at JSS Academy of Higher Education and Research increased over the years?

Yes, JSS AHER packages have risen across the last three NIRF cycles. The PG 3-year (MD/MS) median climbed from Rs 15,50,000 (2022-23) to Rs 19,10,000 (2023-24) to Rs 19,45,000 (2024-25), a roughly 25 percent gain. The UG 5-year MBBS median edged up from Rs 13,55,000 to Rs 13,82,000, and the UG 3-year cohort from Rs 9,75,000 to Rs 9,85,000 over the same period.

Who are the top recruiters at JSS Academy of Higher Education and Research?

JSS AHER's top recruiters are pharmaceutical and healthcare leaders, including Biocon, Dr. Reddy's Laboratories, Himalaya Wellness Company, Cipla, Novartis, Ranbaxy, Parexel, Phoenix and Fortis Hospital, plus in-house clinical roles via JSS Hospital. This recruiter mix reflects JSS AHER's identity as a deemed health-sciences university, so hiring is led by life-sciences and clinical employers rather than IT companies.

What is the MBA and pharmacy placement package at JSS Academy of Higher Education and Research?

For 2023-24, JSS AHER's MBA median package was Rs 5,85,000 with 54 of 58 graduates placed (about 93 percent), while B.Pharm graduates recorded a median of Rs 5,00,000 and M.Pharm graduates Rs 8,35,000. These entry-level medians sit at the base of JSS AHER's distribution, below the medical UG and PG cohorts, and reflect early-career roles in the pharma and management sectors.